Recent Quotes
My Watchlist
Indicators
OGJ 150 Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

97.76 +2.79 (+2.94%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer
From Merck & Co., Inc.
Via Business Wire
News headline image
Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Economy World Trade
News headline image
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
From Merck & Co., Inc.
Via Business Wire
Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices ↗
Via Stocktwits
Topics Workforce
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study ↗
Via Stocktwits
News headline image
Goldman Sachs Just Delivered Bad News for U.S. Investors ... Sort Of. Here's What You Need to Know. ↗
The investment bank's analysts simply recognize how much has changed in just the past few years, and what that means for the near future. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs? ↗
The pharmaceutical giant's post-Keytruda plans continue to take shape. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗
Shares in the biotech company have surged on news of a big pharma takeover. 
Via The Motley Fool
News headline image
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? ↗
Via MarketBeat
News headline image
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment ↗
Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date. 
Via Benzinga
News headline image
2 Healthcare Stocks Worth Your Attention and 1 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and... 
Via StockStory
Topics Stocks
News headline image
Why GRAIL Stock Could Be Biotech’s Next Big Breakout ↗
Via MarketBeat
News headline image
Healthcare Rotation Underway: 3 Stocks Leading the Charge ↗
Via MarketBeat
News headline image
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
News headline image
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
From Merck & Co., Inc.
Via Business Wire
News headline image
Healthcare Sector Navigates Volatile Markets: A Defensive Anchor or Driven by Innovation?
As broader markets grapple with persistent volatility on November 18, 2025, the healthcare sector within the S&P 500 (SPX) finds itself under intense scrutiny. Traditionally viewed as a stalwart... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Which S&P500 stocks are moving on Tuesday? ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
News headline image
Market Movers in Motion: Merck & Co. and Amer Sports Chart Volatile Courses
The financial markets are a constant theater of dynamic shifts, and in recent months, two distinct players – pharmaceutical giant Merck & Co. and global sporting goods powerhouse Amer Sports – have... 
Via MarketMinute
Topics Economy Initial Public Offering Intellectual Property
News headline image
Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything ↗
Via MarketBeat
News headline image
Tech Stocks Drop, Pharma Gains As Sector Rotation Picks Up: What's Moving Markets Tuesday? ↗
Wall Street endured another wave of selling in tech stocks on Tuesday, with the Nasdaq 100 down more than 1% by midday in New York, extending its month-to-date slide to more than 5%. 
Via Benzinga
News headline image
Which S&P500 stocks have an unusual volume on Tuesday? ↗
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the S&P500 stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition ↗
Merck's Winrevair drug achieved its primary goal in the Phase 2 CADENCE study for combined post- and pre-capillary pulmonary hypertension due to HFpEF. 
Via Benzinga
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
News headline image
Merck Announces First-Quarter 2026 Dividend
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Jumps On A Surprise Win; Why It Still Has A Long Road To Go ↗
Merck stock jumped Tuesday on a surprise win for its drug, sotatercept, in patients with pulmonary hypertension. 
Via Investor's Business Daily
Topics Government
News headline image
Top S&P500 movers in Tuesday's pre-market session ↗
Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model. 
Via Investor's Business Daily
News headline image
Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
From Merck & Co., Inc.
Via Business Wire
News headline image
Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring ↗
AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight ↗
With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation. 
Via Benzinga
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>